Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

The simplest version of a drop-off assay includes two TaqMan™ probes targeting the same amplicon: a drop-off probe that spans the mutation hotspot but is uniquely complementary to the wild-type ...

AstraZeneca (NASDAQ:AZN) said its drug Tagrisso has been approved by EU regulators for the treatment of EGFR-mutation ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer ...

Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the ...

In August, the FDA approved Rybrevant in combination with oral EGFR-TKI inhibitor ... metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The FDA approval was ...